everal patients have been reported to have variant dominant forms of Glanzmann thrombasthenia, associated with macrothrombocytopenia and caused by gain-of-function mutations of ITGB3 or ITGA2B leading to reduced surface expression and constitutive activation of integrin α IIb β 3 . The mechanisms leading to a bleeding phenotype of these patients have never been addressed. The aim of this study was to unravel the mechanism by which ITGB3 mutations causing activation of α IIb β 3 lead to platelet dysfunction and macrothrombocytopenia. Using platelets from two patients carrying the β 3 del647-686 mutation and Chinese hamster ovary cells expressing different α IIb β 3 -activating mutations, we showed that reduced surface expression of α IIb β 3 is due to receptor internalization. Moreover, we demonstrated that permanent triggering of α IIb β 3 -mediated outside-in signaling causes an impairment of cytoskeletal reorganization arresting actin turnover at the stage of polymerization. The induction of actin polymerization by jasplakinolide, a natural toxin that promotes actin nucleation and prevents depolymerization of stress fibers, in control platelets produced an impairment of platelet function similar to that of patients with variant forms of dominant Glanzmann thrombasthenia. del647-686β 3 -transduced murine megakaryocytes generated proplatelets with a reduced number of large tips and asymmetric barbell-proplatelets, suggesting that impaired cytoskeletal rearrangement is the cause of macrothrombocytopenia. These data show that impaired cytoskeletal remodeling caused by a constitutively activated α IIb β 3 is the main effector of platelet dysfunction and macrothrombocytopenia, and thus of bleeding, in variant forms of dominant Glanzmann thrombasthenia. 
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Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombasthenia Introduction
Integrin α IIb β 3 (GPIIb/IIIa), the main platelet receptor, is a heterodimeric calciumdependent cell-surface glycoprotein expressed on platelets and megakaryocytes that plays a central role in platelet aggregation and thrombus formation. 1 Recent observations suggest that α IIb β 3 is also involved in proplatelet formation. 2, 3 Integrin α IIb β 3 function depends on two different signal transduction pathways: inside-out and outside-in signaling. Under resting conditions, α IIb β 3 is expressed on platelets in a bent, inactive conformation. Upon platelet activation, inside-out signaling causes α IIb β 3 extension and headpiece opening, leading the receptor to assume an active conformation, to acquire the ability to bind its ligands, mainly fibrinogen, and to initiate platelet aggregation. 4 On the other hand, ligand binding leads α IIb β 3 complexes to cluster, thus triggering outside-in signaling, with phosphorylation of the β 3 cytoplasmic tail, activation of signaling proteins (e.g. Src-family kinases and focal adhesion kinase), and ultimately reorganization of the actin cytoskeleton. 5 Cytoskeletal remodeling, with actin polymerization and depolymerization, is a finely regulated event, 6 and when altered it may lead to impaired platelet function and formation, as observed in patients with mutations of filamin A or with MYH9-RD. 7, 8 Mutations of ITGA2B and ITGB3, the genes coding for integrins α IIb and β 3 , generate Glanzmann thrombasthenia (GT), an autosomal recessive bleeding disorder characterized by absent platelet aggregation and a normal platelet count and volume, due to quantitative or qualitative defects of α IIb β 3 . Heterozygous carriers of GT are usually asymptomatic because 50% of normal α IIb β 3 is sufficient for platelet aggregation, 9 but rare autosomal dominant variants of GT, with platelet dysfunction and macrothrombocytopenia, have been associated with gain-of-function mutations of ITGA2B or ITGB3 leading to reduced expression and constitutive activation of α IIb β 3 .
3,10
We have previously described a hereditary Glanzmannlike platelet disorder transmitted in an autosomal dominant way, associated with macrothrombocytopenia and a bleeding diathesis, due to a heterozygous G>C transversion (c.2134+1G>C) of ITGB3 leading to the deletion of exon 13 and to the loss of 40 amino acids (del647-686) of integrin β 3 .
11 This mutation was the first-described, naturally-occurring deletion of the β-tail domain (β-TD) of integrin β 3 , the membrane-proximal portion of the extracellular domain of the protein. β-TD contributes to maintain the bent, inactive conformation of α IIb β 3 ; 12 in fact, the loss of its disulfide bonds causes constitutive activation of α IIb β 3 , [13] [14] [15] but no information is available on its role in outside-in signaling. Recently, a Japanese family carrying a heterozygous ITGB3 c.2134+1G>A transversion leading to the same integrin β 3 deletion and a similar phenotype was reported. 16 We have previously reported that del647-686 integrin β 3 leads to constitutive activation of α IIb β 3 in patients' megakaryocytes, 3 a finding recently confirmed in transfected 293T cells. 16 A few other heterozygous patients with gain-of-function mutations of ITGB3, mucocutaneous bleeding and macrothrombocytopenia have been reported [17] [18] [19] suggesting that, independently of the mutation, constitutive activation of α IIb β 3 leads to platelet dysfunction and macrothrombocytopenia by a common mechanism that, however, has never been addressed.
Here we show that constitutive activation of integrin α IIb β 3 decreases surface expression of the complex through receptor internalization and permanently triggers outsidein signaling, which leads to altered cytoskeletal reorganization that is the main effector of platelet dysfunction and macrothrombocytopenia, and thus of bleeding, in autosomal dominant GT variant forms.
Methods
Blood samples were taken from healthy volunteers and from two patients carrying the ITGB3c.2134+1G>C mutation. 11 All subjects gave written informed consent in accordance with the Declaration of Helsinki. The study was approved by the ethical committee of the University of Perugia.
Construction of the expression vectors, mutagenesis and transfection
Expression vectors were obtained 20 and Chinese hamster ovary (CHO) cells were transfected as described in the Online Supplementary Data. All experiments were performed 2 days after transfection.
Surface biotinylation, β 3 immunoprecipitation and western blotting
Surface proteins on CHO cells and platelets were biotinylated, and integrin β 3 was immunoprecipitated and analyzed by western blotting as described in the Online Supplementary Data. α IIb β 3 expression and internalization, and α v β 3 expression α IIb β 3 expression on resting or activated platelets or CHO cells 21 was assessed by flow cytometry 22 or by western blotting after biotinylation of membrane proteins and β 3 immunoprecipitation. α v β 3 expression was assessed by flow cytometry. 22 Internalization of α IIb β 3 was assessed by flow cytometry as described elsewhere. 23 Platelet fibrinogen content was quantified by enzyme-linked immunosorbent assay (GenWay Biotech. San Diego, CA, USA). Details are given in the Online Supplementary Data.
Adhesion assay
CHO cells and platelets were layered on human fibrinogen. Platelets were also layered on human von Willebrand factor after treatment with 0.1 U/mL human α-thrombin. 18, 24 Details are given in the Online Supplementary Data.
Protein phosphorylation
CHO cells and platelets were plated on human fibrinogen and protein phosphorylation was assessed as described in the Online Supplementary Data.
Clot retraction
Clot retraction was assessed with CHO cells and platelet-rich plasma 25 as described in the Online Supplementary Data.
Actin polymerization
Actin polymerization in CHO cells and platelets was assessed by flow cytometry as described in the Online Supplementary Data.
Analysis of cytoskeletal proteins
The cytoskeleton was extracted from either resting platelets or platelets that had been stimulated with thrombin as described elsewhere 26 . Cytoskeletal proteins were separated on an acrylamide-gel and stained with Comassie-blue 26 . For details see the Online Supplementary Data.
Mass spectrometry
Protein digestion and peptide analysis were performed as reported previously. 27 Databases were searched using MASCOT v.2.2 and MyriMatch v.2.1.87. 28 Protein assembly for MyriMatch analysis was made using IDPicker v.3.0.
29 Spectral-counts were used for semiquantitative comparisons between controls and patients. For details see the Online Supplementary Data.
Effect of the perturbation of actin polymerization on platelet function
α IIb β 3 activation, platelet aggregation, 30 clot retraction and spreading on fibrinogen 30 were assessed in platelets treated with
Mechanism of platelet dysfunction in dominant GT haematologica | 2016; 101 (1)jasplakinolide to induce actin polymerization 31 as described in the Online Supplementary Data.
Construction of retroviral vectors, retrovirus production and megakaryocyte infection
The bicistronic pMYs-IRES-GFP/α IIb , pRetroX-IRESDsRedExpress/β 3 and pRetroX-IRES-DsRedExpress/β 3 del647-686 expression vectors were obtained, retroviruses produced and megakaryocytes double-infected 32 as described in the Online Supplementary Data.
Megakaryocyte spreading, proplatelet formation and morphology
Spreading and proplatelet formation in murine megakaryocytes 32 were evaluated by immunofluorescence. 3 Proplatelet morphology in human blood was analyzed by immunofluorescence as described elsewhere. 3, 33 For details see the Online Supplementary Data.
Effect of the perturbation of actin polymerization on proplatelet formation
Human megakaryocyte cultures 3 were treated with jasplakinolide (1 mM) for 10 min and then cultured for 16 h. Proplatelet formation, spreading on fibrinogen, proplatelet tip number and diameter were assessed as described above.
Structural consequences of del647-686
To unravel the possible structural consequences of del647-686 the three-dimensional structure of the β-TD was derived from the α v β 3 structure (PDBID-code 4G1E) and visualized using PyMOL (DeLano Scientific, San Carlos, CA, USA).
34

Statistical analysis
Data are expressed as means ± standard deviation. An unpaired t-test or the two-way ANOVA with the Bonferroni post-test was applied, where appropriate, using GraphPad Prism version 5.00 (GraphPad Software, L. Bury et al. 48 haematologica | 2016; 101(1) Figure S1A ,B), confirming previous findings.
3,17-19
Gain-of-function mutant β 3 reduces surface expression of α IIb β 3 by enhancing its internalization Western blotting and flow-cytometry showed decreased surface expression of β 3 but a normal amount of β 3 in cell lysates, both in CHO cells expressing del647-686 integrin β 3 and in heterozygous patients' platelets ( Figures  1A,B) . Confocal microscopy of integrin β 3 -transfected CHO cells showed that mutant β 3 is localized predominantly in the cytoplasm, while normal β 3 is localized predominantly on the cell surface (Online Supplementary Figure  S2) . Mutant α IIb β 3 co-localized with concavalin A and with WGA as shown by fluorescence microscopy, confirming normal synthesis and maturation (Online Supplementary Figure S3) . Moreover, in patients' platelets, cytoplasmic α IIb β 3 co-localized with P-selectin in α-granules but also localized in other cytoplasmic structures, probably the open canalicular and dense tubular systems 35 (Online Supplementary Figure S4) .
The fraction of internalized α IIb β 3 was significantly high- Figure 1C ). Similar findings were observed with resting patients' platelets as compared with control platelets ( Figure 1D ). In accordance, patients' platelets contained more fibrinogen than control platelets ( Figure 1E ) and mutant α IIb β 3 -expressing CHO cells internalized fibrinogen under resting conditions differently from CHO cells expressing normal α IIb β 3 that required activation with DTT to internalize it (Online Supplementary Figure S1C ). However, upon platelet stimulation with ADP or TRAP-6, the internal pool of α IIb β 3 of patient's platelets externalized regularly showing that it is correctly recycled after internalization ( Figure 1F ). α v β 3 expression on patient's platelets was comparable to that on control platelets (control 34.9±8.0% versus patients 37.6±7.1%, P=ns).
Constitutively activated α IIb β 3 triggers outside-in signaling
CHO cells expressing mutant β 3 spread faster on fibrinogen than wild-type cells (Figure 2A) . Spreading of patients' platelets was initially faster ( Figure 2B ), but after 30 min became defective 11 . Moreover, patients' platelets spread spontaneously on von Willebrand factor, unlike control platelets that required α IIb β 3 activation to undergo full spreading 18, 24 ( Figure 2C ). Integrin β 3 Tyr773 and Tyr785, as well as focal adhesion kinase, were constitutively phosphorylated in mutant CHO cells, while they were phosphorylated only after spreading on fibrinogen in control cells. Similarly, constitutive β 3 and focal adhesion kinase phosphorylation was observed in resting patients' platelets but not in control platelets ( Figure 3A-C) .
Finally, clot retraction induced by CHO cells expressing the mutant receptor was decreased ( Figure 3D ) as well as clot retraction of patients' PRP ( Figure 3E ).
Constitutive α IIb β 3 activation leads to impaired cytoskeletal reorganization
The content of polymerized actin (F-actin) of CHO cells expressing each of the heterozygous, β 3 -activating mutants described so far 11, [17] [18] [19] together with normal α IIb was higher than that of CHO cells expressing normal α IIb β 3 , and it did not increase after stimulation with DTT ( Figure 4A ). Similarly, F-actin content was significantly higher in resting patients' platelets as compared with con- Cytoskeletal protein content was higher in resting patients' platelets than in resting control platelets. Moreover, electrophoresis showed three overexpressed bands in patients' platelets when compared to resting control platelets. One had a molecular weight of about 70 kDa (band A) while the other two bands migrated at 55 kDa (bands B and C) ( Figure 4C ). Mass spectrometry showed that band A was mainly composed of fibrinogen α-chain, band B of fibrinogen β-chain, and band C of a fragment of fibrinogen γ-chain (Online Supplementary Tables S1 and S2, Online Supplementary Figure S5 ).
Perturbed cytoskeletal reorganization causes platelet dysfunction
To induce actin polymerization in control platelets we used jasplakinolide, a natural cyclic peptide that induces actin polymerization and stabilizes actin filaments. 31 We first determined that jasplakinolide is able to induce actin polymerization in control platelets (Online Supplementary Figure S6) .
Incubation with jasplakinolide did not affect α IIb β 3 surface expression ( Figure 5A ), but significantly impaired its activation, induced by ADP ( Figure 5B ).
Pre-incubation with jasplakinolide impaired, dosedependently, ADP-induced platelet aggregation ( Figure  5C ), clot retraction ( Figure 5D ) and spreading on fibrinogen ( Figure 5E ). Platelets treated with jasplakinolide (1 mM) resembled patients' platelets with regards to their spreading morphology 11 ( Figure 5F ). These effects were not a consequence of cell death because platelets were still able to expose P-selectin on their surface upon stimulation with 10 mM ADP (resting platelets 2.92±1.33%; ADPstimulated platelets 55.03±3.1%; jasplakinolide-treated resting platelets 4.52±1.8%; jasplakinolide-treated ADPstimulated platelets 57.21±7.9%).
Constitutively activated α IIb β 3 impairs proplatelet formation
The proportion of mutant-β 3 -transduced megakaryocytes extending proplatelets in suspension was not different from that of wild-type megakaryocytes (wild-type megakaryocytes=73.8±19.3%, mutant megakaryocytes=61.4±20.7%; n=5, P=ns). However, proplatelet number was reduced and tip diameter was larger in mutant megakaryocytes ( Figure 6A,B) . Moreover, barbellproplatelets were significantly more asymmetrical (difference between tips: wild-type megakaryocytes=1±0.9 mm, mutant megakaryocytes=2.5±1.1 mm; n=5, P<0.01). Similarly, barbell-proplatelets circulating in peripheral blood of our patient were more asymmetrical than in normal controls (difference between tips: controls=0.5±0.4 µm; patient=1.2±0.8 mm, n=5, P<0.05) ( Figure 6C ).
Mutant β 3 -transduced megakaryocytes adhered normally to fibrinogen (wild-type megakaryocytes=51.2±15.3%, mutant megakaryocytes=44.6±20.1%; n=5, P=ns) but displayed abnormal spreading, reminiscent of what was previously observed with patient's megakaryocytes 3 ( Figure  6D ). In contrast, when megakaryocytes were plated on von Willebrand factor, spreading was not different from that of controls (wild-type megakaryocytes=47.9±19.3%, mutant megakaryocytes=50.2±22.6%; n=5, P=ns), as already observed with patient's megakaryocytes. 3 
Perturbed actin polymerization impairs proplatelet formation
The proportion of jasplakinolide-treated human megakaryocytes extending proplatelets in suspension was not different from that of control megakaryocytes (vehicle=26.3±2.6%; jasplakinolide=26.9±9.3%, n=3, P=ns); however, proplatelet formation was abnormal, with most megakaryocytes displaying a reduced number of proplatelet tips (vehicle=13.9±6.1 tips; jasplakinolide=1.4±1.4 tips, n=3, P<0.01) and a reduced tip diameter (vehicle=2.9±0.9 mm; jasplakinolide=1.7±0.8 mm, n=3, P<0.01) (Figure 7 ). Adhesion to fibrinogen of jasplakinolide-treated megakaryocytes was strongly impaired (vehicle=41.4±5.7%; jasplakinolide=4.6±0.5%, n=3, P<0.01) and the few adhering megakaryocytes did not spread (Figure 7 ).
Structural consequences of del647-686
The β-TD connects the lower β-leg of integrin β 3 to the transmembrane portion and consists of an amphipathic α- Table S1 .
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helix lying across a single β-sheet with four β-strands and four disulfide bonds; it non-covalently associates with the calf-2 domain of α IIb (Figure 8 ). Residues spanning from Lys532 through Gly690 in the lower β-leg stabilize the interactions with integrins α v and α IIb in the bent conformation, and mutations of these residues activate α IIb β 3 and trigger fibrinogen binding. 36 Del647-686 removes the 2, 3, and 4 β-strands, which represent a large interaction interface with the calf-2 domain in both α IIb β 3 12 and α v β 3 , 34 thus destroying the β-TD structure (Figure 8) , hindering the adoption of the bent conformation. The observation that, despite a 40-amino acid deletion, α IIb β 3 is still synthesized and expressed on the surface, confirms that β-TD is a domain important for integrin function/activation but not for β 3 synthesis or dimerization with α IIb .
12
Del647-686 also removes Cys-655 and 663, partners of Cys-608 and 687 in the formation of disulfide bonds. Whether the remaining cysteines would then disulfidelink to one another, exchange with the two α1-helix-loop disulfides, or remain as free sulfhydryls is unknown. However, previous site-directed mutagenesis of Cys-655 and 663 leading to the loss of disulfide bonds, resulted in constitutive activation of α IIb β 3 , [13] [14] [15] suggesting that the same mechanism is responsible for the constitutive α IIb β 3 activation associated with del647-686.
Discussion
Our results show that constitutive activation of α IIb β 3 due to gain-of-function mutations of ITGB3, and the consequent permanent triggering of α IIb β 3 -mediated outside-in signaling, induce a perturbation of cytoskeletal remodeling that leads to platelet dysfunction and impaired proplatelet formation. Starting from the study of platelets from two patients carrying the heterozygous ITGB3 del647-686 mutation 11 we extended our observations to three additional ITGB3 gain-of-function mutations [17] [18] [19] in order to describe a general mechanism that leads to bleeding in patients with dominant variants of GT.
We show that constitutive activation of α IIb β 3 leads to permanent triggering of α IIb β 3 -mediated outside-in signal- 
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ing, as shown by the phosphorylation of β 3 Tyr773, Tyr785 and focal adhesion kinase in patients' resting platelets and in CHO cells expressing del647-686 β 3 , by faster spreading on fibrinogen and spontaneous spreading on von Willebrand factor of patients' platelets, contrarily to control platelets that require α IIb β 3 activation for spreading on von Willebrand factor. 18, 24 Activation of α IIb β 3 is physiologically followed by receptor internalization, a way for limiting platelet aggregation. 37, 38 We show here that enhanced α IIb β 3 internalization is the common mechanism leading to reduced surface expression of α IIb β 3 in patients with GT-like syndromes associated with constitutive activation of α IIb β 3 . 10 In fact, we observed enhanced α IIb β 3 internalization in CHO cells expressing several different ITGB3 gain-of-function mutations [17] [18] [19] as well as in platelets of del647-686 β 3 patients. We have previously shown, by flow cytometry using a set of clones directed toward different epitopes of α IIb β 3 , that our patients' platelets express on average 40% residual α IIb β 3 on their surface if compared with control platelets. 11 We show here that in patients' platelets the ratio between normal and mutant β 3 is maintained on the platelet surface ( Figure 1A) . The same is observed in CHO cells transfected with both wild-type and mutant β 3 (heterozygous cell model) which express an approximately equal amount of α IIb β 3 to that of CHO cells transfected with only mutant β 3 (homozygous cell model) ( Figure  1A,B) . It can, therefore, be speculated that normal α IIb β 3 is passively internalized along with the mutant one.
Confocal microscopy revealed that in patients' platelets
Mechanism of platelet dysfunction in dominant GT Enhanced α IIb β 3 internalization was associated with an increased platelet content of fibrinogen. The intra-platelet fibrinogen pool is largely generated by its internalization mediated by activated α IIb β 3 , 39, 40 although internalization by inactive α IIb β 3 has also been reported. 41 Increased fibrinogen content in the patients' platelets is, therefore, in accordance with constitutively activated α IIb β 3 .
Given that integrin β 3 is a component of the vitronectin receptor α v β 3 , we measured α v β 3 expression on patients' platelets and found it to be comparable to that on control platelets. Therefore, our mutation, like others previously reported, 9 influences α v β 3 and α IIb β 3 expression differently. In normal conditions, α IIb β 3 -mediated outside-in signaling leads to a reorganization of the cytoskeleton that is required for platelet aggregation, clot retraction and spreading. Cytoskeletal actin reorganization is a finely regulated process with consecutive phases including actin polymerization, which enhances the cytoskeletal rigidity required for platelet shape change, and then depolymerization, which restores the cytoskeletal plasticity required for aggregation and clot retraction. 42 An alteration of actin dynamics and cytoskeletal remodeling can, therefore, impair platelet function. 
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We show here that CHO cells expressing ITGB3 gainof-function mutations, as well as del647-686 β 3 -bearing platelets, have an increased F-actin content under resting conditions and show impaired clot retraction, suggesting that actin turnover is arrested at the stage of polymerization due to permanently triggered outside-in signaling. This is in line with the earlier spreading on fibrinogen of mutant platelets becoming defective at later time points, because actin turnover is arrested at the stage of polymerization and further cytoskeletal remodeling is no longer possible. Moreover, patients' platelets had an enhanced cytoskeletal-associated protein content as compared with control platelets, and fibrinogen α, β and γ chains were found to be associated with the cytoskeleton.
In order to assess whether impaired cytoskeletal remodeling recapitulates the platelet features associated with α IIb β 3 -activating ITGB3 mutations we used jasplakinolide, a natural cyclic peptide that induces actin polymerization by promoting actin nucleation and by preventing depolymerization of stress fibers. 31 Jasplakinolide-treated control platelets showed impaired α IIb β 3 activation, reduced aggregation, altered spreading on fibrinogen and clot retraction, a phenotype resembling that of del647-686 platelets. 11 Altogether, these data are compatible with a model in which α IIb β 3 constitutive activation causes the arrest of cytoskeletal remodeling at the stage of polymerization, thus impairing platelet aggregation, clot retraction and spreading. On the other hand, reduced α IIb β 3 surface expression does not seem to contribute significantly to platelet dysfunction because incubation of normal platelets with jasplakinolide induced the same platelet dysfunction observed in patients with variant GT without affecting α IIb β 3 surface expression. Moreover, α IIb β 3 internalization is not triggered by actin polymerization but depends on the constitutive activation of the receptor.
Cytoskeletal remodeling is also crucial for proplatelet formation: in fact actin polymerization leads to the amplification of proplatelet ends, thus increasing tip number, 43 and regulates platelet size. 35, 36 Impaired actin remodeling in megakaryocytes may thus perturb platelet formation, and in fact defects in actin-related proteins were shown to lead to thrombocytopenia and to the production of platelets with altered dimensions. [44] [45] [46] [47] We induced actin polymerization by incubating control megakaryocytes with jasplakinolide and indeed we observed impaired proplatelet formation.
Murine megakaryocytes transduced with del647-686 human β 3 and wild-type human α IIb showed impaired proplatelet formation, with a reduced number of abnormally large proplatelet tips. These data confirm our previous observations with peripheral blood CD34 + -derived patients' megakaryocytes 3 and prove that the 2134+1 G>C mutation is the cause of macrothrombocytopenia. We also observed that barbell-proplatelets produced by transduced murine megakaryocytes are asymmetrical, similar to those found in patients' peripheral blood. This is therefore probably responsible for the platelet anisocytosis observed in patients with the del647-686 mutation. 11 Our observations confirm that α IIb β 3 plays a role in proplatelet formation 3, 18, 48 and show that when outside-in signaling is constitutively triggered, cytoskeletal reorganization is disturbed and altered proplatelet formation and preplatelet maturation occur.
In conclusion, we show that gain-of-function mutations of ITGB3 generating constitutive activation of α IIb β 3 lead to receptor internalization and to the arrest of cytoskeletal remodeling in platelets and megakaryocytes which, in turn, generate platelet dysfunction and perturb the finely regulated process of proplatelet formation leading to macrothrombocytopenia. Reduced platelet number and platelet dysfunction in patients with dominant variants of GT are both consequent to the cytoskeletal perturbation induced by the constitutive α IIb β 3 -mediated outside-in signaling. 
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